Can-Fite BioPharma to initiate Phase III trial of piclidenoson to treat rheumatoid arthritis

Can-Fite BioPharma, an advanced clinical stage drug development company, has reached an agreement with the European Medicines Agency (EMA) to design a global Phase III trial for piclidenoson (CF101), a new A3 adenosine receptor agonist (A3AR) small m…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news